Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Adaptive Biotechnologies Corp (ADPT) vs Becton Dickinson and Co (BDX) Price & Performance

Adaptive Biotechnologies CorpTrade
Becton Dickinson and CoTrade

Price performance (Past 24H)

Key statistics

Adaptive Biotechnologies Corp vs Becton Dickinson and Co — how do they compare? Adaptive Biotechnologies Corp trades at $25.5 (market cap $4.04B), while Becton Dickinson and Co trades at $180.75 (market cap $49.41B). The key difference: Becton Dickinson and Co is far larger — about 12.2× Adaptive Biotechnologies Corp's market cap, and Becton Dickinson and Co pays a 2.32% dividend while Adaptive Biotechnologies Corp pays none. Which is the better fit depends on your goals.

ADPTBDX
Market Cap
$4.04B$49.41B
Sector
HealthHealth
52-Week High
$25.45$185.39
52-Week Low
$12.30$138.62
Enterprise Value
$4.10B$65.51B
Dividend Yield
2.32%

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Adaptive Biotechnologies Corp

Adaptive Biotechnologies Corp is a commercial-stage company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is test authorized by the FDA for the detection and monitoring of minimal residual disease in patients with select blood cancers.

Read more on ADPT

About Becton Dickinson and Co

Becton, Dickinson is the world's largest manufacturer and distributor of medical surgical products, such as needles, syringes, and sharps-disposal units. The company also manufactures diagnostic instruments and reagents, as well as flow cytometry and cell-imaging systems. BD Interventional (largely the former Bard business) accounts for 23% of revenue. International revenue accounts for 44% of the company's business.

Read more on BDX